NN Group Beats Expectations, On Track For 2028 Guidance
NN Group delivered strong FY 2025 results, with operating capital generation of €2.1 billion and free cash flow exceeding €1.6 billion, surpassing expectations. NN's robust Solvency II ratio of 220% and consistent capital generation underpin confidence in achieving 2028 targets of €2.2 billion operating capital and €1.8 billion free cash flow. Shareholder rewards are expanding, with a €3.88 per share dividend (5.7% yield) and a €350 million buyback, targeting a 4%-5% share count reduction by 2028.
IWMI: Russell 2000 Covered Call ETF, Outstanding Double-Digit Distribution Yield, Strong Performance Track-Record
IWMI tracks the Russell 2000 and writes covered calls on a portion of its holdings. It sports a massive 13.5% distribution yield. Upside potential is significantly reduced, although not zero. The fund has performed well since inception, with double-digit CAGR.
2 Bruised Tech Stocks on the Fast Track to AGI
The race to achieve artificial general intelligence (AGI) is on, and the race might be closer than investors realize.
Is Rivian on Track to Launch the Affordable R2 Ahead of Schedule?
RIVN starts R2 validation builds at its Illinois plant, signaling momentum toward first-half 2026 deliveries of its affordable electric SUV.
Advantage Energy: La Niña On Track
Advantage Energy stands to benefit from La Niña-driven cold weather. AAVVF remains heavily exposed to natural gas. Rising natural gas demand may improve returns on new wells.
Wabtec Stays On Track For A Strong 2026
Wabtec Corporation remains a Buy, supported by robust backlog growth and improving margins across both freight and transit divisions. WAB's $386 million NYC hybrid locomotive order and international contracts, including a $4.2 billion Kazakhstan deal, reinforce multi-year revenue visibility. Normalized earnings per share have exceeded $2.00 for three consecutive quarters, with FY 2026 EPS projected at $10.18.
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track
Novo Nordisk A/S launches oral Wegovy in the U.S. at aggressive introductory pricing, aiming to secure early market share and first-mover advantage. NVO faces imminent semaglutide patent expiry in China, triggering a wave of local competition and likely sharp margin compression in 2026. Novo's China revenue, about 6.5% of total, is expected to decline, but U.S. oral GLP-1 ramp should offset regional headwinds.
Shoe Carnival's Transformation Into Shoe Station Is Still On Track
Shoe Carnival is executing a turnaround by converting stores to the higher-margin Shoe Station brand, targeting middle-income consumers. Short-term headwinds from rebranding are offset by a $50 million buyback authorization and robust free cash flow supporting both buybacks and dividends. SCVL trades at a discount on forward EV/EBITDA, with a 2026 price target of $22.08 per share—22% above current levels.
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.
Kymera's Eczema Drug Gets Fast Track Designation in the United States
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
Victoria's Secret: Round Trip For The Stock, Back On Track
Victoria's Secret & Co. delivered a strong Q3 beat and raised full-year guidance, signaling a turnaround in performance. Net sales grew 9% year-over-year to $1.472 billion, with comparable sales up 8% and adjusted losses narrowing sharply. Management now guides FY net sales to $6.45–$6.48 billion and adjusted EPS to $2.40–$2.65, reflecting robust Q4 expectations.
ETFs to Keep Your Portfolio on Track in the Long Term
Despite November's volatility, optimism is returning to Wall Street. Discover how long-term strategies combined with ETFs can help investors build resilient portfolios ready to capture the next phase of the bull market.
